Navigation Links
Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change!
Date:3/19/2011

1; making it arguably the most potent such compound under development. Rx100 protects against damage to both the bone marrow as well as the critical cells of the small intestine.

Testing of Rx100 has demonstrated its unique properties in comparison to other drug candidates in the pipeline. Of significance is the fact that Rx100: a) is a small molecule, b) is essentially nontoxic at therapeutic doses, c) has a long shelf life, d) is nonimmunogenic, e) and provides effective treatment of ARS when administered up to 72 hours after exposure to lethal, whole-body radiation.

Dr. W. Shannon McCool, RxBio's CEO, points out that: "Rx100 is unique among radioprotectants / radiomitigators in that it boosts natural mechanisms that promote and sustain cell survival in almost every cell type and at the same time inhibits the cascade leading to programmed cell death (apoptosis). Thus, Rx100 augments the good and shuts down the bad. While other products shut down essential cellular signaling mechanisms involved in radiation-induced cellular injury and tend to lack specificity and/or may be toxic, Rx100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival and antiapoptosis. Among its actions, Rx100 protects critical stem cells. Rx100 can be formulated for a wide range of patient types – from infants to the elderly – and can be administered either orally or subcutaneously."

In addition, Dr. Gabor Tigyi, RxBio's CSO, comments that: "Rx100 is a potent protector of the GI tract. This drug provides significant protection to the gut from radiation as well as other toxic substances such as cholera toxin. Among its actions, Rx100 maintains the mucosal barrier of the GI tract. It prevents severe diarrhea and the entry of bacterial toxins into the blood stream – both potentially severe side effects." RxBio has recently presented it's initial NHP data at the BARDA meeting that took place in January, 2011, in Washington. Th
'/>"/>

SOURCE RxBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
2. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
3. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
4. ChemImage Works to Improve Existing Methods of Imaging Untreated Fingerprints on Paper Substrates
5. Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
6. Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations
7. Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome
8. Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation!
9. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
10. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
11. New near-field radiation therapy promises relief for overheating laptops
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Sept. 7 On Thursday, October,18, 2007, Wyeth (NYSE: ... 2007,third quarter. The Company will hold a one-hour conference ... October 18, 2006. Interested,investors and others may listen to ... Internet webcast, which may be accessed by visiting our ...
... Richard Gabriel, Chief,Executive Officer of DNAPrint Genomics, ... be featured in an exclusive interview with, http://www.wallst.net ... September 10 at 11,a.m. EDT. The interview will ... p.m.,EDT on September 10. The interview will ...
... York City 5:30-7:30 p.m. (ET), SAN DIEGO, Sept. ... focused on developing products for,minimally disruptive surgical treatments for ... reception for institutional investors and,analysts at the Waldorf=Astoria Hotel ... 5:30 p.m. to 7:30 p.m. ET. The reception ...
Cached Biology Technology:WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics 2NuVasive to Host Investor Reception on September 11, 2007 2NuVasive to Host Investor Reception on September 11, 2007 3NuVasive to Host Investor Reception on September 11, 2007 4
(Date:10/22/2014)... discovery by Northwestern Medicine® scientists helps explain how bipolar ... to new drug therapies to treat the mental illness. ... -- the same method recognized with the 2014 ... into brain tissue from mice with bipolar-like behaviors. In ... discovered tiny "nanodomain" structures with concentrated levels of ANK3 ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... biochemists have developed an approach that allows them to ... in a protein. The scientists were then able ... protein based on structural information, a novel outcome that ... Academy of Sciences. , Professor of biochemistry John Markley, ...
... are so crucial to survival that the brains of all ... long enough to allow the animal to eat, drink -- ... from researchers at the University of Chicago, published early online ... that by activating "OFF" cells and shutting down "ON" cells ...
... classic "Flowers for Algernon," but adds a happy ending, UCLA ... reverse the attention deficits linked to the leading genetic cause ... Biology reports the findings, which were studied in mice bred ... , The results proved so hopeful, that the Food and ...
Cached Biology News:Scientist uses form to explain function of key building blocks of life 2Brainstem blocks pain to protect key behaviors 2Brainstem blocks pain to protect key behaviors 3Recreating 'Flowers for Algernon' with a happy ending 2Recreating 'Flowers for Algernon' with a happy ending 3
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: